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Abstract
Background: Retinoids are potent growth inhibitory and differentiating agents in a variety of
cancer cell types. We have shown that retinoids induce growth arrest in all pancreatic cancer cell
lines studied, regardless of their p53 and differentiation status. However, the mechanism of growth
inhibition is not known. Since TGF-β2 is markedly induced by retinoids in other cancers and
mediates MUC4 expression in pancreatic cancer cells, we investigated the role of TGF-β in retinoic
acid-mediated growth inhibition in pancreatic cancer cells.
Results: Retinoic acid markedly inhibited proliferation of two cell lines (Capan-2 and Hs766T) in
a concentration and time-dependent manner. Retinoic acid increased TGF-β2 mRNA content and
secretion of the active and latent forms of TGF-β2 (measured by ELISA and bioassay). The
concentrations of active and TGF-β2 secreted in response to 0.1 – 10 μM retinoic acid were
between 1–5 pM. TGF-β2 concentrations within this range also inhibited proliferation. A TGF-β
neutralizing antibody blocked the growth inhibitory effects of retinoic acid in Capan-2 cells and
partially inhibitory the effects in Hs766T cells.
Conclusion: These findings indicate that TGF-β can cause growth inhibition of pancreatic cancer
cells, in a p53-independent manner. Furthermore, it demonstrates the fundamental role of TGF-β
in growth inhibition in response to retinoic acid treatment is preserved in vitro.
Background
Pancreatic adenocarcinoma is currently the fourth leading
cause of cancer death in the United States [1] and histo-
logically constitutes 90% of pancreatic tumors. The diag-
nosis of pancreatic cancer is usually established at a
locally advanced or metastatic stage. Lack of effective
treatments and resistance to conventional therapy con-
tribute to an extremely poor prognosis [1,2]. Vitamin A
(retinol) and its natural derivatives (retinoids) are
involved in several important physiological processes
such as reproduction, cell proliferation, differentiation
and embryonic development [3]. Human clinical trials
have demonstrated retinoic acid suppresses development
of oral premalignant lesions, head and neck and skin can-
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cer [4]. Patients with acute promyelocytic leukemia are
particularly sensitive to retinoic acid treatment. Their
response rates are in the range of 90% with retinoic acid
monotherapy [5]. Retinoic acid can arrest growth in a
number of different cell types [6,7].
One member of the retinoic acid receptor family (collec-
tively called RAR) recognize two natural stereo isomers of
retinoic acid, all-trans retinoic acid (ATRA), and 9-cis retin-
oic acid. In contrast, another receptor family (collectively
called RXR) only recognizes 9-cis retinoic acid. The pleio-
tropic effects of retinoids are mediated with each individ-
ual receptor sub-type controlling distinct gene expression
patterns important for cell growth and differentiation.
Target genes include transcription factors, enzymes,
cytokines and growth factors [8]. In some cancer cell
types, retinoic acid-mediated growth inhibition is associ-
ated with reduced expression of transcription factors such
as c-myc, c-myb, p53, pRB and also decreased expression
of epidermal growth factor receptor [4]. However, the fac-
tors directly involved in mediating the anti-proliferative
effects of retinoids have so far not been elucidated.
It has been previously demonstrated, that by optimizing
the treatment conditions, a broad panel of pancreatic can-
cer cell lines that were reported to be resistant to retinoic
acid were sensitized to the anti-proliferative effects and
differentiation induction by retinoic acid in vitro and in
vivo [9]. Retinoic acid also induces apoptosis in pancreatic
cancer cells [10]. The purpose of the present study was to
examine TGFβ as a likely candidate in mediating the
growth inhibitory effects of retinoic acid in pancreatic
cancer cells.
Members of the transforming growth factor-β (TGF-β)
superfamily are known to potently inhibit the prolifera-
tion of many epithelial cell types [11]. TGF-β is secreted in
a latent inactive complex in association with the latency
associated peptide (LAP). Latent TGF-β (LTGF) is bound
to additional high molecular weight proteins that are
associated with LAP. The mechanisms of TGF-β activation
include, proteolysis, enzymatic deglycosylation, acid-
treatment, ROS and radiation [12]. Acid treatment of the
conditioned media (CM) activates latent TGF-β, probably
by denaturing the LAP either by conformational change or
by disturbing the interaction between LAP and TGF-β
[12]. TGF-β signaling is initiated by binding to the type I
and type II cell-surface receptors, both of which are serine/
threonine kinases. The Smad anchor for receptor activa-
tion (SARA), which is a membrane-associated protein,
escorts unphosphorylated Smad2 and Smad 3 to the
receptor, which in turn phosphorylates these Smad pro-
teins [13]. These then associate with Smad4 and enter the
nucleus and, together with other transcription factors,
activate transcription of various target genes [14]. The
impact of the loss of components of TGF-β signaling is
seen in pancreatic and colon cancer. In pancreatic cancer,
the DPC-4 (deleted in pancreatic Cancer-4/Smad-4) gene
is inactivated in by homozygous deletion or intragenic
mutation in 50% of cases [15]. This might be expected to
abolish TGF-β signaling, however, recent studies have
clearly demonstrated Smad-4 independent signaling path-
ways in pancreatic cancer cells as well as in several other
systems [16-19]. TGF-β and retinoic acid are associated in
both a physiological and pathological context [20,21].
Both TGF-β and retinoic acid inhibit the growth of retinal
pigment epithelial cells, bone marrow progenitor cells,
and human cervical and breast cancer cells [22-25]. TGF-
β2 mediates the expression of MUC-4 in retinoic acid
treated pancreatic cancer cells [26]. The TGF-β2 isoform is
selectively induced by retinoic acid in keratinocytes [27].
Retinoic acid also induces the activation of latent TGF-β
and its receptor [15,21,28-31]. Furthermore, neutralizing
antibodies against TGF-β can block retinoic acid-induced
growth inhibition of several types of cells including kerat-
inocytes and leukemia cells. [32,33].
Based on the previous studies establishing a relationship
between retinoic acid and TGF-β, this growth factor
appeared to be a likely candidate to mediate the growth
inhibitory effects of retinoic acid in pancreatic cancer. This
role was investigated in the following studies.
Results
Growth Studies with retinoic acid
Retinoic acid inhibited the growth of Capan-2 and
Hs766T cells in a concentration and time-dependent
manner. Cell counts measured as percent of control are
shown in Figure 1. After 6 days of treatment, Hs766T and
Capan-2 cell numbers were reduced to approximately
68% and 75% of control with 0.1 μM retinoic acid and to
20% and 32% of control in cells treated with the highest
concentration (10 μM), respectively. Retinoic acid caused
a similar reduction in 3H-thymidine incorporation in
Capan-2 and Hs766T cells (Figure 2). On days 2 and 4,
3H-thymidine incorporation was virtually undetectable
with 10 μM retinoic acid in both cell lines. A decrease in
3H-thymidine incorporation could be detected as early as
12 hours [9].
Effect of conditioned media on the growth of in CCL-64 
Cells
The conditioned media from Capan-2 and Hs766T cells
treated with retinoic acid inhibited the growth of the CCL-
64 cells in a concentration dependent manner, as shown
in Figure 3. Significant growth inhibition of the CCL-64
cells was observed in both untreated {(active TGF-β) top
panel} and acid activated {(total TGF-β) bottom panel}
samples. In untreated samples a 1:2 dilution of media was
the most effective, with a significant inhibition of growthMolecular Cancer 2007, 6:82 http://www.molecular-cancer.com/content/6/1/82
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at 5 and 10 μM retinoic acid in both cell lines. Marked
growth inhibition of CCL-64 cells was seen at a 1:10 dilu-
tion of acid-activated conditioned media (data not
shown).
Effect of TGF-β immunoneutralization on CCL-64 cell 
proliferation in response to conditioned media from 
retinoic acid-treated pancreatic cancer cells
To confirm the specificity of the TGF-β bioassay in CCL-
64 cells, immunoneutralization studies were carried out
using different concentrations (25. 50 and 100 μg/ml) of
a pan-specific TGF-β antibody. The results showed that 25
μg/ml of pan-specific antibody was sufficient to signifi-
cantly reduce the growth inhibitory effects of the condi-
tioned media on the CCL-64 cells. Furthermore, there was
no significant difference between CCL-64 cells treated
with 25, 50 and 100 μg/ml of the antibody in the condi-
tioned media (data not shown). Therefore, subsequent
studies with CCL-64 cells were conducted with 25 μg/ml
antibody. The attribution of the stimulation of 3H-thymi-
dine incorporation in CCL-64 cells by untreated and acid-
treated conditioned media to the presence of TGF-β is sup-
ported by the observation that the stimulation was pre-
vented by antibodies to TGF-β (Figure 4).
Effect of all-trans retinoic acid on incorporation of 3H-thymi- dine in CAPAN-2 (top panel) and Hs766T (bottom panel)  cells over 48 and 96 hours Figure 2
Effect of all-trans retinoic acid on incorporation of 3H-thymi-
dine in CAPAN-2 (top panel) and Hs766T (bottom panel) 
cells over 48 and 96 hours. Concentration-dependent inhibi-
tion of DNA synthesis was observed in both cells lines. Two-
way ANOVA: Capan-2: Concentration effect F(3,16) = 576, P 
< 0.0001; Time effect F(1,16) = 2.62, P = 0.125; Interaction 
F(3,16) = 28.9, P < 0.0001; Hs766T: Concentration effect 
F(3,24) = 846, P < 0.0001; Time effect F(1,24) = 0.05, P = 
0.817; Interaction F(3,24) = 57.0, P < 0.0001. Data are 
expressed as counts per minute (CPM), bars represent 
means ± SEM.
Effect of retinoic acid on the proliferation of human pancre- atic cancer cells Figure 1
Effect of retinoic acid on the proliferation of human pancre-
atic cancer cells. All-trans-retinoic acid significantly inhibited 
the proliferation of CAPAN-2 (top panel) and Hs766T cells 
(bottom panel), in a concentration and time-dependent man-
ner. Two-way ANOVA: Capan-2: Concentration effect 
F(3,48) = 46.6; Time effect F(5,48) = 147.8; Interaction 
F(15,48) = 5.79, all P < 0.0001; Hs766T: Concentration effect 
F(3,24) = 61.9; Time effect F(5,24) = 86.9; Interaction 
F(15,24) = 5.92, all P < 0.0001. Cell counts are expressed as 
percentage of control, bars represent means ± SEM.Molecular Cancer 2007, 6:82 http://www.molecular-cancer.com/content/6/1/82
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Quantification of TGF-β2 mRNA
TGF-β2 mRNA expression was significantly increased by 4
and 6-fold after 18 hours of treatment with retinoic acid
in Hs766T and Capan-2 cells, respectively (Figure 5).
However at later time points such as 24 and 48 hours the
expression levels were not significantly increased over
control.
Quantification of active and total TGF-β2 by enzyme-
linked immunosorbent assay (ELISA)
In a pilot study, active TGF-β2 concentrations were below
the detection limit in the conditioned media from retinoic
acid-treated pancreatic cancer cells. To bring the concen-
trations into the detectable range, the media was concen-
trated 10-fold for subsequent experiments. Retinoic acid
treatment resulted in a significant concentration-depend-
ent increase of both active and total TGF-β2 in the condi-
tioned media from Capan-2 and Hs766T cells (Figure 6).
These results clearly indicate that treatment of pancreatic
cancer cells with retinoic acid significantly increases both
the active and the precursor forms of TGF-β2 in a time and
concentration dependent manner. Moreover, these results
are also consistent with the bioassay data.
Growth inhibition studies with TGF-β2
Based on the results from the ELISA, we determined a
range for treatment of the pancreatic cancer cells with
TGF-β2. This range (0.3–300 pM) spans the range seen for
both active and total TGF-β2.
Effect of TGF-β pan-neutralizing antibody on inhibition of 3H- thymidine incorporation by CCL-64 cells Figure 4
Effect of TGF-β pan-neutralizing antibody on inhibition of 3H-
thymidine incorporation by CCL-64 cells. TGF-β antibody 
prevented growth inhibition of CCL-64 cells induced by CM 
from CAPAN-2 (top panel) and Hs766T (bottom panel) cells 
treated with 0.1 and 5 μM retinoic acid. One way ANOVA: 
Capan-2: F(5,17) = 101.9; HS766T: F(5,17) = 113.3, both P < 
0.0001. Data are expressed as counts per minute (CPM), 
bars represent means ± SEM. Significance of individual com-
parisons after Bonferroni's multiple comparison test is indi-
cated by *** = P < 0.001.
The effect of pancreatic cancer cell-conditioned media (CM)  on 3H-thymidine incorporation by mink lung epithelial (CCL- 64) cells Figure 3
The effect of pancreatic cancer cell-conditioned media (CM) 
on 3H-thymidine incorporation by mink lung epithelial (CCL-
64) cells. CCL-64 cells were exposed to non-activated CM 
(with only active TGFβ, top panels) and acid-activated CM 
(total TGFβ, bottom panels) from CAPAN-2 and Hs766T 
cells treated with retinoic acid for 48 hours. The growth of 
the CCL-64 cells was significantly attenuated by both types of 
CM. One way ANOVA: Capan-2, non-activated CM: F(3,11) 
= 40.6, P < 0.0001; Capan-2, activated CM: F(3,11) = 16.5, P 
= 0.0009; Hs766T, non-activated CM: F(2,11) = 39.2, P < 
0.0001; Hs766T, activated CM: F(2,11) = 231, P < 0.0001. 
Data are expressed as counts per minute (CPM), bars repre-
sent means ± SEM. Significance of individual comparisons 
after Dunnett's multiple comparison test is indicated by ** = 
P < 0.01.Molecular Cancer 2007, 6:82 http://www.molecular-cancer.com/content/6/1/82
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Results of the growth inhibition studies with TGF-β2 are
shown in Figure 7. Growth inhibition was studied by thy-
midine incorporation and cell counting (data not shown)
and the results obtained with these two methods were
comparable. After 4 days of treatment, 1 pM TGF-β2 sig-
nificantly inhibited the growth of both cell lines. High
concentrations (100–300 pM) caused cell death in
Capan-2, while Hs766T cells were only growth inhibited
at these concentrations. The TGF-β2 concentration of 1
pM falls within the active range of TGF-β2 measured by
ELISA. These results indicate that the amount of active
TGF-β2 secreted by the pancreatic cancer cells in response
to retinoic acid is capable of mediating the growth inhib-
itory effects of the retinoic acid.
Effect of TGF-β immunoneutralization on retinoic acid 
inhibited proliferation of pancreatic cancer cells
Treatment with the pan-neutralizing TGF-β antibody pre-
vented the inhibitory effects of retinoic acid on of Capan-
2 cells and partially prevented the effect in Hs766T cells
(Figure 8).
Discussion
In the present study, we have established a role of TGF-β2
in mediating the growth inhibitory effects of retinoic acid
in human pancreatic adenocarcinoma cells. Retinoic acid
increased the expression of TGF-β2 mRNA as well as the
concentration of active and total TGF-β2. In addition to
measurement by immunoassay, the biological activity
TGF-β2 in the conditioned media of retinoid treated cells
Effect of retinoic acid on secretion of TGF-β2 (active and  total) by human pancreatic cancer cells measured by ELISA Figure 6
Effect of retinoic acid on secretion of TGF-β2 (active and 
total) by human pancreatic cancer cells measured by ELISA. 
Treatment with retinoic acid, stimulated secretion of active 
(top panels) and total (bottom panels) TGF-β2, from Capan-
2 (left panels) and Hs766T cells (right panels), in a time and 
concentration-dependent manner Two-way ANOVA: 
Capan-2, active TGF-β2: Concentration effect F(3,16) = 36.4, 
P < 0.0001; Time effect F(3,16) = 356, P < 0.0001; Interaction 
F(9,16) = 4.47, P < 0.005; Capan-2, total TGF-β2: Concentra-
tion effect F(3,16) = 396; Time effect F(3,16) = 37.9; Interac-
tion F(9,16) = 78.3, all P < 0.0001; Hs766T, active TGF-β2: 
Concentration effect F(2,17) = 155; Time effect F(3,17) = 
27.4; Interaction F(6,17) = 27.8, all P < 0.0001. Hs766T, total 
TGF-β2: Concentration effect F(2,18) = 378, P < 0.0001; 
Time effect F(3,18) = 6.99, P = 0.0026; Interaction F(6,18) = 
7.8, P = 0.0003. TGF-β2 concentrations are expressed as 
fmol/ml. Bars represent means ± SEM.
Effect of retinoic acid on TGF-β2 mRNA quantified by real- time RT-PCR in human pancreatic cancer cells Figure 5
Effect of retinoic acid on TGF-β2 mRNA quantified by real-
time RT-PCR in human pancreatic cancer cells. CAPAN-2 
(top panel) and Hs766T cells (bottom panel) were treated 
with 0.1–10 μM retinoic acid for 18 hours. Retinoic acid 
caused a significant concentration-dependent increase in the 
TGF-β2 mRNA expression in these cells. Values were nor-
malized to levels of mRNA for GAPDH, which was also used 
as a loading control. One way ANOVA: Capan-2: F(3,11) = 
15.0, P = 0.0012; HS766T: F(3,11) = 4.72, P = 0.034. Data are 
expressed as fold-change from untreated cells, bars repre-
sent means ± SEM. Significance of individual comparisons 
after Dunnett's multiple comparison test is indicated by * = P 
< 0.05, ** = P < 0.01.Molecular Cancer 2007, 6:82 http://www.molecular-cancer.com/content/6/1/82
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was evaluated by growth inhibition of CCL-64 mink lung
epithelial cells. While this is a biologically relevant find-
ing, it is neither quantitative nor specific for either TGF-β
isoform. It is possible that a factor other than TGF-β may
inhibit the growth of CCL-64 cells, however the bioassay
is thought to be very specific for this peptide [34]. Further-
more, the specificity of TGF-β was confirmed using pan-
TGF-β neutralizing antibodies, which prevented the
growth inhibition of CCL-64 cells induced by the condi-
tioned media. TGF-β2 levels were quantitatively assessed
by ELISA. The disadvantage of ELISA is that the concentra-
tion of the peptide is determined by the epitope the anti-
body recognizes and may, therefore measure, non-
biologically active form. However, in combination these
assays indicate a significant increase in both the secreted
latent and biologically active form of TGF-β from retinoid
treated cells.
Retinoic acid stimulated secretion of latent and active
TGF-β2 from Hs766T cells in a time and concentration-
dependent manner. In contrast, while the TGF-β2
response in Capan-2 was concentration dependent, meas-
ured concentrations of active TGF-β2 decreased with time.
Effect of pan-neutralizing TGF-β antibody on retinoic acid- induced inhibition of 3H-thymidine incorporation in human  pancreatic cancer cells Figure 8
Effect of pan-neutralizing TGF-β antibody on retinoic acid-
induced inhibition of 3H-thymidine incorporation in human 
pancreatic cancer cells. The TGF-β antibody prevented the 
growth inhibitory effects of retinoic acid in CAPAN-2 cells 
(top panel) and partially inhibited the effect in Hs766T cells 
(bottom panel). One way ANOVA: Capan-2: F(3,11) = 7.02, 
P = 0.0125; HS766T: F(3,11) = 136, P < 0.0001. Significance 
of individual comparisons after Bonferroni's multiple compar-
ison test is indicated by * = P < 0.05, *** = P < 0.001. Data 
are expressed in counts per minute (CPM). Bars represent 
means ± SEM.
Effect of TGF-β2 on 3H-thymidine incorporation in human  pancreatic cancer cells Figure 7
Effect of TGF-β2 on 3H-thymidine incorporation in human 
pancreatic cancer cells. Treatment of CAPAN-2 (top panel) 
and HS766T cells (bottom panel) with TGF-β2 significantly 
inhibited incorporation of 3H-thymidine in a concentration-
dependent manner. A significant time-dependent effect was 
seen in Capan-2, but not Hs766T cells. Two-way ANOVA: 
Capan-2, Concentration effect F(7,32) = 181; Time effect 
F(1,32) = 104; Interaction F(7,32) = 18.2, all P < 0.0001; 
Hs766T: Concentration effect F(7,32) = 26.1, P < 0.0001; 
Time effect F(1,32) = 1.72, P = 0.199; Interaction F(7,32) = 
4.96, P = 0.0007. Data are expressed in counts per minute 
(CPM). Bars represent means ± SEM.Molecular Cancer 2007, 6:82 http://www.molecular-cancer.com/content/6/1/82
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Secreted TGF-β concentration measured on the second
and fourth day should be higher than the first and third
day, respectively. Since the media was changed at 48 and
96 hours, more TGF-β should accumulate by the second
and fourth day. Therefore the lower levels seen at these
time points must reflect a degree of degradation of TGF-β
in the media. Thus the actual concentrations of TGF-β2
may be higher than those measured.
We have reported that cell lines that were previously
shown to be resistant to the growth inhibitory effects of
retinoic acid, were responsive when growth conditions
were optimized. All isoforms of retinoic acid (9-cis, 13-cis
and all trans) were equipotent in inducing growth inhibi-
tion in these cell lines [9]. Rosewicz et al showed that
growth inhibition observed in Capan-2 cells in response
to retinoic acid treatment correlated with decrease in PKC
alpha expression levels [35]. Retinoic acid also induced
differentiation at the morphological and biochemical lev-
els in pancreatic cancer cells. Changes in morphology cor-
related with changes in metabolism such as increased
carbonic anhydrase activity and mucin production
[36,37]. In this study we quantified active TGF-β2 levels
induced by retinoic acid in pancreatic cancer cells. We did
not examine the effect of retinoic acid on TGF-β1 expres-
sion and activation because retinoic acid has no effect on
the expression on TGF-β1 in pancreatic cancer cells [26].
The growth inhibitory effects of retinoic acid could also be
partially mediated by p21waf1 and TGF-β pathway. Since
p21 mRNA and protein levels were found to be elevated
by retinoic acid.
Retinoic acid induced TGF-β2 production in human ade-
nocarcinoma cells and normal rat kidney fibroblasts [38].
We observed a transient increase in TGF-β2 mRNA in
response to retinoic acid treatment followed by an
increase in the active form of TGF-β2 as estimated by
ELISA. This response can be transient since TGF-β is
secreted in an inactive latent complex and is kept associ-
ated with the extracellular matrix. Retinoic acid can acti-
vate latent TGF-β2. Retinoic acid enhances the production
of the tissue-type plasminogen activator which increases
cell associated plasmin activity and activates latent TGF-β
[27,28]. It is likely that a similar mechanism exists in pan-
creatic cancer cells. Retinoic acid can regulate the tran-
scription of the TGF-β2 and TGF-β receptors, by the
characteristic binding of its receptors to Sp1 and GC box
motifs in the respective promoters. Retinoic acid treat-
ment or RAR/RXR-overexpression strengthens the affinity
of Sp1 to GC box motifs in the promoter by potentially
inducing a conformational change in Sp1 thereby enhanc-
ing the transactivation of these genes [39].
Based on the results from the ELISA, we determined a
range for treatment of the pancreatic cancer cells with
TGF-β2. This range (0.3–300 pM) covers the expression
for both active and total TGF-β2. Upon treating cancer
cells with TGF-β2 we found that even the lower concentra-
tions were sufficient to induce growth inhibition and cell
death. These results indicate that the amounts of active
TGF-β2 generated by the pancreatic cancer cells treated
with retinoic acid are capable of mediating its growth
inhibitory effects.
Immunoneutralization studies using pan-specific TGF-β
antibody only partially blocked the growth inhibitory
effects of retinoic acid in HS766T cells. There are several
possible reasons for this; firstly, there could be insufficient
antibody to neutralize the larger amount of TGF-β
secreted from this cell line in response to 5 μM retinoic
acid. Secondly, the antibody could bind to the large
amount of latent TGF-β peptide, therefore making it una-
vailable for neutralizing the active TGF-β. Finally, TGF-β
may be one of several factors involved in mediating the
effects of retinoic acid.
The induction of latent and active TGF-β2 is independent
of the DPC-4 status of the cells, since, activation was seen
in cells with wild-type SMAD-4 (Capan-2) as well as in
Hs766T cells, which have a homozygous deletion of this
gene. Furthermore, both cell lines were sensitive to the
growth inhibitory effects of TGF-β2, in a concentration
and time-dependent manner. This indicates that SMAD
independent pathways must be involved in mediating the
growth inhibitory effects of TGF-β, at least in Hs766T
cells. Growth inhibitory effects of TGF-β have been previ-
ously reported in SMAD-4 null pancreatic and colon can-
cer cells [16,19]. These SMAD-4 independent mechanisms
of TGF-β signaling, in pancreatic cancer are not clearly
understood. The activated TGF-β receptor complex acti-
vates several non SMAD-4 signaling pathways, including
MAPK (p44/42 or ERK), PP2A/P70S6K, Rho A, TAK/
MEKK1 [19] and phosphoinositide 3-kinase (PI3K) [11].
Further analysis of the molecular interactions mediating
the responses to retinoic acid in SMAD-4 null cells will
unravel the pathways involved. Since both cell lines have
inactivating mutations in the p53WAF-1 gene, the inhibi-
tory effects of TGF-β in these cell lines are also clearly
independent of p53WAF-1 signaling.
Conclusion
Retinoic acid induces growth inhibition in pancreatic can-
cer cells regardless of their degree of differentiation, k-ras,
p53 and DPC-4 status [16,40]. Our current data is consist-
ent with these previously published results. We have dem-
onstrated in a step by step manner, that TGF-β is involved
in mediating the growth inhibitory effects of retinoic acid.
Smad-4 independent pathways are implicated in mediat-
ing the growth inhibitory effects of TGF-β in Hs766T cells.
However, other factors are also likely to be involved. ThisMolecular Cancer 2007, 6:82 http://www.molecular-cancer.com/content/6/1/82
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is the first direct evidence of the involvement of TGF-β in
mediating retinoic acid induced growth inhibition in pan-
creatic cancer. In conclusion, we have clearly demon-
strated that the growth inhibitory effects of retinoic acid
are partially, but significantly mediated through the
increased expression of TGF-β2.
Materials and methods
Cell lines and treatment with retinoic acid
Well-differentiated (Capan-2) and poorly-differentiated
(Hs766T) human pancreatic cancer cell lines were used
for these studies. Both cell lines were grown as sub-conflu-
ent monolayer cultures in Dulbecco's modified Eagle's
medium/Ham's F-12 medium (1:1) supplemented with
10% fetal calf serum, 100 units/ml penicillin and 100 μg/
ml streptomycin. Cells were incubated at 37°C in a
humidified atmosphere with 5% CO2. All experiments
were carried out in the log phase of growth after the cells
had been plated for 24 hours. A stock 100 mM solution of
all-trans retinoic acid (Sigma Chemicals, St. Louis, MO) in
DMSO was stored in 50 μl aliquots in dark brown tubes at
-80°C. After dilution in medium, this stock gave final con-
centrations between 1 nM and 10 μM, with DMSO con-
centrations < 0.01%. All experiments with retinoic acid
were carried out in subdued yellow light.
Cells were treated with retinoic acid in serum free condi-
tions, using media containing a 1:1 mixture of DMEM and
Ham's F-12 media, containing 4 mM L-glutamine, 1 mM
pyruvate, 10 mM HEPES and 2.5 g/L glucose. Cell prolif-
eration studies were conducted in 24-well plates. Media,
with or without fresh retinoic acid were renewed every 48
hours.
Cell counting and 3H-thymidine incorporation
Treated cells were washed with phosphate buffered saline
(PBS) and detached using 0.25% trypsin solution contain-
ing 1 mM EDTA. Cells in suspension were counted using
an automated particle counter (Model Z1, Coulter Elec-
tronics).
After treatment with retinoic acid or medium the cells
were washed with PBS and incubated with 3H-thymidine
(1 μCi/well, 25 Ci/mmol, Amersham Life Science, Arling-
ton Heights, IL) in serum free medium for 2 hours. The
medium was removed and the cells were washed three
times with PBS. Cellular proteins were then precipitated
twice with ice cold 10% TCA for 15 minutes, to remove
acid soluble materials including free thymidine. The pre-
cipitates were solubilized in 1.0 M NaOH and counted in
a liquid scintillation counter.
Measuring bioactivity of TGF-β in conditioned medium 
using CCL-64 cells
To measure the bioactivity of secreted TGF-β, mink lung
epithelial (CCL-64) cells were treated with the condi-
tioned medium from retinoic acid-treated and untreated
control cells. To prepare conditioned medium, cancer
cells were treated with 0.1, 5 and 10 μM retinoic acid for
72 hours, washed twice with PBS, and incubated in serum
free fresh medium containing 0.1% BSA for 24 hours.
Conditioned medium was then collected in siliconized
tubes and aliquots were stored at -20°C. Repeated freez-
ing and thawing was avoided. For bioassay of active TGF-
β, CCL-64 cells were seeded in 10% FBS containing MEM
medium in 24 well plates (20,000 cells/well) for 24 hours
and then cultured in serum-free medium for 24 hours.
Cells were plated in triplicate for each concentration of
retinoic acid. CCL-64 cells were incubated for 24 hours in
CM. The proliferation of CCL-64 cells was measured by
inhibition of 3H-thymidine incorporation as described
above.
To demonstrate the presence of total TGF-β (latent and
active), diluted 1:2 conditioned media (1 ml) was added
directly or following acidification to pH 2.0 with 1N HCl,
incubation at 20°C for 20 minutes and readjustment of
the pH to 7.4 with 1N NaOH, to the plated CCL-64 cells.
RNA preparation from pancreatic cancer cells
Total RNA preparations from retinoic acid treated pancre-
atic cancer cells was carried out using the total RNA mini-
prep kit (DMN10, Sigma, St. Louis, MO). Pancreatic
cancer cells grown in T-25 cm2 tissue culture flasks were
washed twice with PBS and lysed with the lysis buffer con-
taining guanidine thiocyanate and 2-mercaptoethanol to
release the RNA and inactivate the RNases. Lysates were
spun through a filtration column to remove cellular
debris and shear DNA. The filtrate was then applied to a
silica column and washed and the RNA eluted according
to the manufacturer's instructions. The RNA was then
treated with 1 μl DNase (Ambion, Austin, TX). The quality
and the concentration of the RNA were determined spec-
trophotometrically.
Preparation of cDNA by reverse-transcription
The volume corresponding to 1 μg total RNA from retin-
oic acid treated and untreated pancreatic cancer cells was
mixed with 1 μl of oligo dT primers (Invitrogen, Carlsbad,
CA) and incubated at 68–70°C for 10 mins and then put
on ice to separate the RNA molecules. A master-mix was
then prepared using 5× first-strand buffer, 2'-deoxynucle-
oside 5'-triphosphate (dNTP) (10 mM), ribonuclease
(RNase) inhibitor (25 U) and Moloney Murine leukemia
virus reverse transcriptase all purchased from Invitrogen
(Carlsbad, CA). Total reaction volume (25 μl) was then
subjected to RT-PCR (42°C-60 minutes, 95°C-5 minutes,Molecular Cancer 2007, 6:82 http://www.molecular-cancer.com/content/6/1/82
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4°C-5 minutes). The resulting complementary DNA
(cDNA) was stored at -20°C.
Real-time PCR
The cDNA (40 ng) obtained from reverse transcription
was subjected to quantitative real-time polymerase chain
reaction (RT-PCR) using the SYBER Green detection sys-
tem (Applied Biosystems, Foster City, CA). GAPDH from
control and treated samples was used as a loading control
and also to normalize the transcripts, since GAPDH tran-
scripts are unaltered in response to retinoic acid. The RT-
PCR forward and reverse primers for TGF-β2 and GAPDH
were as follows:
TGF-β2 forward:GGGTGGAAATGGATACACGAA
TGF-β2 reverse:AGGACCCTGCTGTGCTGAGT
GAPDH forward:TGGGCTACACTGAGCACCAG
GAPDH reverse: GGGTGTCGCTGTTGAAGTCA
Quantification of secreted TGF-β2 by ELISA
Quantification of both the active and latent forms of TGF-
β2 was carried out using the TGF-β2 Emax™Enzyme-Linked
Immunosorbent Assay system (Promega, Madison, WI).
Capan-2, and Hs766T cells were treated with retinoic acid
for 24, 48, 72 and 96 hours, conditioned media were col-
lected as described above. For assaying active TGF-β2,
samples were concentrated 10-fold by the freeze drying
and reconstituting in one-tenth of the original volume in
"sample buffer" (provided in the assay kit). To study the
expression of total TGF-β2, samples were acid activated as
described above. For consistency, the TGF-β2 ELISA and
bioassay with CCL-64 cells were carried out at the same
time with the same samples.
Cell growth studies with TGF-β2
TGF-β2 (R&D Systems, Minneapolis, MN) was dissolved
in 100 mM formic acid with 0.1% BSA and 50 mg/ml lac-
tose. The solution was divided into aliquots and freeze
dried. Upon reconstitution in 1 ml of media the TGF-β2
concentration was 200 nM. The cells were then treated
with different concentrations of TGF-β2, which includes
the concentration range in conditioned media from the
three cell lines, 0.3–300 pM. Thymidine incorporation
was measured as described above.
Immunoneutralization studies
To confirm the presence of TGF-β in the conditioned
media, mediating the growth inhibitory effects on the
CCL-64 cells, immunoneutralization studies were carried
out using different concentrations (25, 50 and 100 μg/ml)
of a pan-specific TGF-β antibody. CCL-64 cells were
treated with cancer cell conditioned media diluted 1:2,
with or without the pan-neutralizing TGF-β antibody as
previously described (R&D Systems, Minneapolis, MN)
[34]. Cell growth was measured by 3H-thymidine incor-
poration as described above.
Statistical analysis
Data was analyzed by one way analysis of variance
(ANOVA) with Dunnett's post test for multiple compari-
sons against control and Bonferroni's test for pre-selected
comparisons between groups. Two-way ANOVA was also
performed for experiments studying the effects of differ-
ent treatments over time.
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